(Q35013390)

5 August 2017

1 reference

title

Development of oral cladribine for the treatment of multiple sclerosis (English)

1 reference

5 August 2017

0 references

1

Hans-Peter Hartung

1 reference

5 August 2017

3

Bernd Kieseier

1 reference

5 August 2017

2

Orhan Aktas

1 reference

5 August 2017

author name string

Giancarlo Comi Giancarlo Comi

series ordinal

4

1 reference

5 August 2017

language of work or name

1 reference

1 February 2010

1 reference

5 August 2017

1 reference

5 August 2017

volume

257

1 reference

5 August 2017

issue

2

1 reference

5 August 2017

page(s)

163-170

1 reference

Defining the clinical course of multiple sclerosis: Results of an international survey

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00415-009-5359-0

Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-009-5359-0

2-Chlorodeoxyadenosine: a newer purine analog active in the treatment of indolent lymphoid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-009-5359-0

Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-009-5359-0

Cladribine: an investigational immunomodulatory agent for multiple sclerosis

21 January 2018

1 reference

12 December 2020

Interleukin-8 and RANTES levels in patients with relapsing-remitting multiple sclerosis (RR-MS) treated with cladribine

1 reference

12 December 2020

Multiple sclerosis--the plaque and its pathogenesis

1 reference

12 December 2020

FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system

1 reference

12 December 2020

The role of B cells in multiple sclerosis: rationale for B-cell-targeted therapies

1 reference

12 December 2020

Toward the development of rational therapies in multiple sclerosis: what is on the horizon?

1 reference

12 December 2020

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

1 reference

12 December 2020

The natural history of multiple sclerosis

1 reference

12 December 2020

Emerging oral therapies for multiple sclerosis

1 reference

12 December 2020

Cladribine in treatment of chronic progressive multiple sclerosis

1 reference

12 December 2020

Patient preferences for oral versus intravenous palliative chemotherapy

1 reference

12 December 2020

Strategies for optimizing adherence to highly active antiretroviral therapy: lessons from research and clinical practice

1 reference

12 December 2020

Th17 Cells in MS and Experimental Autoimmune Encephalomyelitis

1 reference

12 December 2020

Dose-escalation trial of cladribine using five daily intravenous infusions in patients with advanced hematologic malignancies

1 reference

12 December 2020

New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab

1 reference

12 December 2020

The potential role for cladribine in the treatment of multiple sclerosis: clinical experience and development of an oral tablet formulation

1 reference

12 December 2020

Interventions for enhancing medication adherence

1 reference

12 December 2020

Mechanisms of action for treatments in multiple sclerosis: Does a heterogeneous disease demand a multi-targeted therapeutic approach?

1 reference

12 December 2020

Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: Possible role of nucleoside kinase(s)

1 reference

12 December 2020

Cladribine impedes in vitro migration of mononuclear cells: a possible implication for treating multiple sclerosis

1 reference

12 December 2020

A pilot study of 2-chloro-2'-deoxyadenosine in the treatment of systemic lupus erythematosus-associated glomerulonephritis

1 reference

12 December 2020

Effect of immunosuppressive cladribine treatment on serum leucocytes system in two-year clinical trial in patients with chronic progressive multiple sclerosis

1 reference

12 December 2020

Patient preference in the management of postmenopausal osteoporosis with bisphosphonates

1 reference

12 December 2020

Relationship of deoxycytidine kinase and cytoplasmic 5'-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine.

1 reference

12 December 2020

The epidemiology of multiple sclerosis in Europe.

1 reference

12 December 2020

Neutralisation of IL12 p40 or IL23 p40 does not block inflammation in multiple sclerosis

1 reference

12 December 2020

Successful pregnancy after cladribine therapy for hairy cell leukemia

1 reference

12 December 2020

Roles of immunoglobulins and B cells in multiple sclerosis: from pathogenesis to treatment

1 reference

12 December 2020

Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes

1 reference

12 December 2020

Pathogenic CD8(+) T cells in multiple sclerosis

1 reference

12 December 2020

The treatment of chronic progressive multiple sclerosis with cladribine

1 reference

12 December 2020

Diagnosis and treatment of multiple sclerosis

1 reference

12 December 2020

The effect of cladribine on some parameters of blood and cerebrospinal fluid in patients with relapsing-remitting multiple sclerosis (RR-MS)

1 reference

12 December 2020

Cladribine (2-chlorodeoxyadenosine)

1 reference

12 December 2020

Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias

1 reference

12 December 2020

Mitoxantrone for multiple sclerosis causing acute lymphoblastic leukemia

1 reference

12 December 2020

Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study

1 reference

12 December 2020

The safety profile of low-dose cladribine in refractory rheumatoid arthritis. A pilot trial

1 reference

12 December 2020

Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia

1 reference

12 December 2020

Treatment of multiple sclerosis and other autoimmune diseases with cladribine

1 reference

12 December 2020

Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines

1 reference

12 December 2020

Clinical and toxicological aspects of the antineoplastic drug cladribine: a review

1 reference

12 December 2020

A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease

1 reference

12 December 2020

The relation between intermittent dosing and adherence: preliminary insights

1 reference

12 December 2020

Patients' preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer

1 reference

12 December 2020

Durable response but prolonged cytopenia after cladribine treatment in relapsed patients with indolent non-Hodgkin's lymphomas: results of a Japanese phase II study

1 reference

12 December 2020

Patient satisfaction with an injection device for multiple sclerosis treatment

1 reference

12 December 2020

1 reference

12 December 2020

1 reference

12 December 2020

Managing self-injection difficulties in patients with relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Second cancer risk in hairy cell leukemia: analysis of 350 patients

1 reference

12 December 2020

The clinical pharmacokinetics of cladribine

1 reference

12 December 2020

The immunopathology of multiple sclerosis: an overview

1 reference

12 December 2020

10.1007/S00415-009-5359-0

Identifiers

DOI

1 reference

5 August 2017

1 reference